Therapy of Essential Hypertension With Kinzal®/ Kinzalplus®

Completed

• Conditions: Hypertension
• Interventions: Drug: Telmisartan (Kinzal/Pritor, BAY68-9291) + Hydrochlorothiazide; Drug: Telmisartan (Kinzal/Pritor, BAY68-9291)

• Registration Number: NCT00927537
• Lead Sponsor: Bayer

Brief Summary

The efficacy and tolerability of an antihypertensive treatment with Telmisartan is followed over 3-4 months

Detailed Description

Not available

Basic Information
|
Recruitment & Eligibility
|
Study & Design

Study Timeline

• Study Start: 2008-04
• Study First Submitted: 2009-06-24
• Study First Submitted QC: 2009-06-24
• Study First Posted: 2009-06-25
• Primary Completion: 2011-10
• Study Completion: 2011-10
• Status Verified: 2013-09
• Last Update Submitted: 2013-09-01
• Last Update Posted: 2013-09-04

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2052

Inclusion Criteria

• Hypertensive patients seen by the physician requiring antihypertensive treatment

Read More

Exclusion Criteria

• According to the local drug information

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Group 2	Telmisartan (Kinzal/Pritor, BAY68-9291) + Hydrochlorothiazide	-
Group 1	Telmisartan (Kinzal/Pritor, BAY68-9291)	-

Primary Outcome Measures

Name	Time	Method
Blood pressure	After 1-2 weeks, 1month, 3-4 months

Secondary Outcome Measures

Name	Time	Method
Change in Mean heart rate (bpm)	Baseline and 3-4 month
Change in Mean Weight (kg)	Baseline and 3-4 month
Change in Mean laboratory parameters (total cholesterol, LDL, HDL, triglyceride, fasting blood glucose)	Baseline and 3-4 month
Patient Medical History: Duration of hypertension, Pre-treatment of hypertension, Comorbidities and Concomitant treatment	Baseline
Final evaluation of efficacy (very good, good, sufficient, insufficient) and tolerability (very good, good, sufficient, insufficient) of treatment by the physician.	After 3-4 month